MONTREAL, Nov. 12, 2019 /PRNewswire/ - Pharmascience Inc. is proud to announce that the US Food and Drug Administration (FDA) communicated on October 31, 2019, that the abbreviated new drug ...
PRINCETON, N.J., April 6, 2025 /PRNewswire/ -- Luye Pharma Group today announced that ERZOFRI ® (paliperidone palmitate) extended-release injectable suspension is now available for commercial sale in ...
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of the antipsychotic Paliperidone Janssen-Cilag International (Janssen-Cilag ...
The US Food and Drug Administration (FDA) has approved a 6-month injection form of the long-acting atypical antipsychotic paliperidone palmitate (Invega Hafyera, Janssen Pharmaceuticals) for the ...
The Janssen Pharmaceutical Companies of Johnson & Johnson announced FDA approval of Invega Hafyera, a twice-yearly injectable antipsychotic for adults with schizophrenia. The approval of this 6-month ...
PP6M is a long-acting injectable antipsychotic designed to reduce the number of injections patients with schizophrenia receive. A supplemental New Drug Application (sNDA) for paliperidone palmitate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback